NeoStem, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is NeoStem, Inc.’s Form 10-Q for the quarter ended March 31, 2015, not a 2014 Q1 filing. This differs from the request metadata identifying Lisata Therapeutics, Inc.
Business context and reporting period
NeoStem described itself as a clinical-stage cell-therapy company with a clinical-services and manufacturing business through Progenitor Cell Therapy (PCT). Its principal programs included NBS20 for metastatic melanoma, NBS10 for ischemic injury following heart attack, and NBS03D for type 1 diabetes. The financial comparisons below are for the three months ended March 31, 2015 and March 31, 2014.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 or prior balance-sheet date |
|---|---|---|
| Revenue | $3.17 million | $4.06 million |
| Cost of revenue; gross result | $3.37 million; gross loss of $0.20 million (about -6%) | $3.83 million; gross profit of about $0.23 million (about 6%) |
| Research and development | $6.80 million | $4.76 million |
| Selling, general and administrative | $11.09 million | $8.97 million |
| Operating loss | $18.09 million | $13.50 million |
| Net loss attributable to NeoStem common stockholders; loss per share | $19.19 million; $0.51 | $13.68 million; $0.49 |
| Cash used in operating activities | $14.24 million | $11.25 million |
| Cash and cash equivalents at period end | $19.13 million | $19.17 million at December 31, 2014 |
| Working capital; stockholders’ equity | $11.6 million; $50.4 million | Not stated as comparable figures in the filing text |
At March 31, 2015, marketable securities were nil; the company reported total assets of $118.8 million and total liabilities of $68.8 million. Long-term debt was $15.0 million in carrying value, comprising $2.24 million current and $12.76 million long-term; notes payable totaled about $1.72 million. The filing also reported $18.81 million of acquisition-related contingent consideration liabilities. Interest expense was $0.55 million, compared with $0.09 million a year earlier.
Material changes versus the prior comparable period
- Revenue fell 22%, primarily because of lower clinical-services revenue. Management said the reported decline was affected by an additional net $1.2 million revenue deferral in Q1 2015, principally because process-development contracts are recognized on completion.
- Processing and storage services revenue rose about 43% to $1.06 million, while clinical services revenue fell about 43% to $1.46 million. Deferred costs rose to $3.62 million from $2.57 million at year-end; advance billings related to these contracts were also higher.
- Operating expenses increased 21%. R&D rose 43%, including $1.9 million for immuno-oncology and $1.0 million for potential critical-limb-ischemia work in Japan. SG&A rose 24%, with management citing executive-transition costs and activity following the CSC acquisition.
- Operating cash use increased about $3.0 million year over year. Financing included $7.4 million of common-stock proceeds from the Aspire agreement; investing cash inflow primarily reflected the sale of about $7.0 million in marketable securities.
- Common shares outstanding increased to 39.42 million at March 31 from 36.78 million at December 31, 2014. The filing reported 40.15 million shares outstanding as of May 4, 2015.
Outlook, risks and unusual items
- Management said current cash, revenue-generating activities and access to the 2014 Aspire stock-purchase agreement were expected to fund the business through the next 12 months. It also stated that additional capital would be needed for development programs and PCT growth, and that financing may not be available on acceptable terms. Equity funding may dilute shareholders.
- The Intus Phase 3 trial of NBS20 was planned to randomize 250 patients; the first patient was randomized in April 2015, and interim analysis was targeted for Q4 2017. Management estimated the study would cost about $43 million. These are forward-looking estimates and milestones, not guaranteed outcomes.
- Management characterized PreSERVE AMI findings as interim trends and signals from follow-up data, including dose-related trends in cardiac outcomes; the study was to continue through three-year follow-up. The filing cautioned that ongoing analysis could alter the apparent results.
- The company planned to initiate the NBS03D Phase 2 study in late 2015 or 2016, depending on resources. Trial execution, enrollment, regulatory outcomes, financing, and commercialization were identified as significant uncertainties.
- Oxford Finance had provided a $15 million loan at an 8.5% interest rate, with a further $5 million available only if specified conditions—including an NBS10 strategic arrangement and at least $10 million upfront—were met by September 19, 2015. The first-patient randomization in Intus extended the interest-only period to April 1, 2016. The company reported covenant compliance at March 31, 2015.
- On May 4, 2015, NeoStem entered a new Aspire agreement for up to $30 million over 24 months, subject to share-count and pricing limits. Separately, $11.7 million remained available under the 2014 Aspire agreement at March 31, subject to a 1.4 million-share issuance limit.
- Unusual reported items included $0.55 million of expense from remeasurement of acquisition-related contingent consideration and executive-management transition costs. Management reported no material change in previously disclosed legal proceedings or risk factors, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer and period: the source is NeoStem’s Q1 2015 filing, despite the request metadata naming Lisata Therapeutics and 2014 Q1.
- Track cash burn, working capital, and the availability and actual use of both Aspire agreements; the stated 12-month funding expectation depends partly on financing access.
- Verify Intus enrollment, costs, timing, and clinical results as the Phase 3 trial progresses, and distinguish interim PreSERVE AMI signals from final outcomes.
- Monitor dilution from stock issuance, the Oxford loan repayment schedule and conditional additional borrowing, and the $18.81 million contingent-consideration liability.
- Assess whether PCT contract completions convert deferred revenue into recognized revenue and whether service margins improve; Q1 gross profit was negative.